AAX Biotech to attend BioJapan 2025 (virtual)

We are pleased to announce that our CEO, Maria Lisa Knudsen will be representing AAX Biotech at BioJapan 2025 (virtually), from 8–10 October 2025. 

As Japan’s leading life science partnering event, BioJapan provides a unique platform to foster global collaborations and explore opportunities at the intersection of science and industry. 

Maria will be highlighting how AAX Biotech’s platforms — Seqitope®, for high-resolution and high throughput epitope mapping, and Opti-mAb®, for stabilizing scFv antibodies — are helping to accelerate the development of next-generation antibody therapeutics with greater therapeutic impact. 

We look forward to connecting with current and future pharma and biotech partners, exchanging insights, and building relationships that bring innovative medicines closer to patients.